Response Assessment to Erythropoietin-Zeta (Epo-Alpha Biosimilar) Therapy in Low-Risk Myelodysplastic Syndromes.

Calogero VetroValeria Di GiacomoDonato ManninaSilvana MagrinAntonio MulèMaria Enza MitraSergio SiragusaAndrea DuminucoBruno GaribaldiMaria Cristina Emanuela VadalàFrancesco Di RaimondoGiuseppe Alberto Maria Palumbo

Published in: Journal of clinical medicine (2022)

Compared with data from the literature, this prospective study revealed that EPO-zeta is a safe and effective therapeutic option in low-risk MDS patients.

Keyphrases

end stage renal disease
chronic kidney disease
newly diagnosed
ejection fraction
systematic review
prognostic factors
electronic health record
stem cells
bone marrow
mesenchymal stem cells
data analysis